25.8.2026 07:00:08 CEST | Thor Medical ASA | Non-regulatory press releases
Thor Medical, a leading supplier of high-purity isotopes to the
radiopharmaceutical industry, today announced that Brede Ellingsæter, CFO and
COO of Thor Medical, will transition to a dedicated role as Chief Operating
Officer, allowing him to focus fully on the operational and commercial
development of the company.
With AlphaOne now in commercial production and supplying customers, Thor Medical
is strengthening its management structure with dedicated leadership of finance,
as well as operational and commercial activities. A recruitment process for a
new CFO has been initiated.
"Brede has been instrumental in building Thor Medical into the company it is
today, from bringing AlphaOne into operation to building our commercial
position. As we now scale the business, his experience and ability to execute
will be key to our operational and commercial growth. I am very pleased to have
Brede taking on this dedicated role and look forward to strengthening Thor
Medical's position as a leading global supplier to the radiopharmaceutical
industry with Brede by my side," said Jasper Kurth, CEO of Thor Medical.
Brede will remain CFO until his successor takes up the position, before
transitioning fully to his role as Chief Operating Officer.
CONTACTS
* Mathias Nilsen Reierth, Head of Communications and Corporate Affairs, +47 988
05 724, mathias.reierth@thormedical.com
ABOUT THOR MEDICAL ASA
Thor Medical is a leading supplier of high-purity isotopes to the
radiopharmaceutical industry. The Company's proprietary production platform
combines advanced separation technology with industrial-scale manufacturing
capacity to deliver a reliable, scalable and cost-efficient supply of
alpha-emitting radioisotopes. Thor Medical supports radiopharmaceutical
companies from early-stage development to commercialization enabling scale-up of
next-generation targeted cancer therapies.
Thor Medical's product portfolio includes lead-212 (Pb-212) and its precursor
isotopes thorium-228 (Th-228) and radium-224 (Ra-224). Based on naturally
occurring thorium, Thor Medical's production process requires neither
irradiation nor nuclear reactors, providing significant cost advantages while
minimizing radioactive waste.
Guided by its vision to become a world-leading enabler for targeted cancer
therapies, Thor Medical is committed to improving millions of lives by powering
the next generation of precision cancer treatment with high-purity isotopes.
Thor Medical is headquartered in Oslo, Norway, and listed on the Oslo Stock
Exchange under the ticker symbol TRMED. For more information, visit
www.thormedical.com - http://www.thormedical.com.
ATTACHMENTS
Download announcement as PDF.pdf -
https://kommunikasjon.ntb.no/ir-files/17848634/19036304/15874/Download%20announc
ement%20as%20PDF.pdf
ntb.no/ir-files/17848634/19036304/15874/Download%20announc\
ement%20as%20PDF.pdf\